安进公司最新公布的Maritide扩展研究结果显示,在为期52周的延长试验期间,绝大多数接受较低月度剂量或季度剂量给药的参与者,成功维持了在二期临床试验第一阶段所达到的体重减轻效果。这项扩展研究旨在评估不同给药方案对体重维持的长期影响,初步数据表明药物在延长用药周期后仍能保持疗效稳定性。
安进公司最新公布的Maritide扩展研究结果显示,在为期52周的延长试验期间,绝大多数接受较低月度剂量或季度剂量给药的参与者,成功维持了在二期临床试验第一阶段所达到的体重减轻效果。这项扩展研究旨在评估不同给药方案对体重维持的长期影响,初步数据表明药物在延长用药周期后仍能保持疗效稳定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.